Industry Focus
Healthcare: How Much Do Share Prices Matter In Big-Cap Biotech?
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:18:02
- Mas informaciones
Informações:
Sinopsis
We compare Biogen's and Celgene's current valuations and consider what might be in store for Gilead Sciences now that its new hepatitis C drug is approved.
